These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24665588)

  • 1. [Comparison of the kinetics of granulocytes and lymphocytes between influenza A/H1N1/pdm09 and seasonal influenza A].
    Hirotsu N; Hasegawa T; Saisho Y; Murate J; Ikematsu H; Iwaki N; Kawai N; Kashiwagi S
    Kansenshogaku Zasshi; 2014 Jan; 88(1):117-25. PubMed ID: 24665588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proinflammatory chemokines are major mediators of exuberant immune response associated with Influenza A (H1N1) pdm09 virus infection.
    Thomas M; Mani RS; Philip M; Adhikary R; Joshi S; Revadi SS; Buggi S; Desai A; Vasanthapuram R
    J Med Virol; 2017 Aug; 89(8):1373-1381. PubMed ID: 28198028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long term effectiveness of adjuvanted influenza A(H1N1)pdm09 vaccine in children.
    Örtqvist Å; Bennet R; Hamrin J; Rinder MR; Lindblad H; Öhd JN; Eriksson M
    Vaccine; 2015 May; 33(22):2558-61. PubMed ID: 25869891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seroconversion to seasonal influenza viruses after A(H1N1)pdm09 virus infection, Quebec, Canada.
    Baz M; Papenburg J; Hamelin ME; Ouakki M; Skowronski DM; De Serres G; Boivin G
    Emerg Infect Dis; 2012 Jul; 18(7):1132-4. PubMed ID: 22710312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-reactive immunity against influenza viruses in children and adults following 2009 pandemic H1N1 infection.
    Ahmed MS; Jacques LC; Mahallawi W; Ferrara F; Temperton N; Upile N; Vaughan C; Sharma R; Beer H; Hoschler K; McNamara PS; Zhang Q
    Antiviral Res; 2015 Feb; 114():106-12. PubMed ID: 25513756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13.
    Kissling E; Valenciano M; Buchholz U; Larrauri A; Cohen JM; Nunes B; Rogalska J; Pitigoi D; Paradowska-Stankiewicz I; Reuss A; Jiménez-Jorge S; Daviaud I; Guiomar R; O'Donnell J; Necula G; Głuchowska M; Moren A
    Euro Surveill; 2014 Feb; 19(6):. PubMed ID: 24556348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seroprevalence of seasonal and pandemic influenza a in Kuala Lumpur, Malaysia in 2008-2010.
    Sam IC; Shaw R; Chan YF; Hooi PS; Hurt AC; Barr IG
    J Med Virol; 2013 Aug; 85(8):1420-5. PubMed ID: 23765779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza pneumonia among adolescents and adults: a concurrent comparison between influenza A (H1N1) pdm09 and A (H3N2) in the post-pandemic period.
    Yang SQ; Qu JX; Wang C; Yu XM; Liu YM; Cao B
    Clin Respir J; 2014 Apr; 8(2):185-91. PubMed ID: 24106842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2).
    Valenciano M; Kissling E; Reuss A; Jiménez-Jorge S; Horváth JK; Donnell JM; Pitigoi D; Machado A; Pozo F;
    Vaccine; 2015 Jun; 33(24):2813-22. PubMed ID: 25936723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15.
    Valenciano M; Kissling E; Reuss A; Rizzo C; Gherasim A; Horváth JK; Domegan L; Pitigoi D; Machado A; Paradowska-Stankiewicz IA; Bella A; Larrauri A; Ferenczi A; ; Lazar M; Pechirra P; Korczyńska MR; Pozo F; Moren A;
    Euro Surveill; 2016; 21(7):pii=30139. PubMed ID: 26924024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased Mortality in Seasonal H3N2 Patients Compared with those with Pandemic 2009 H1N1 in Taiwan, 2009-2010.
    Huang SY; Huang WC; Chen YC; Tsai CY; Lee IK
    Am J Trop Med Hyg; 2017 Dec; 97(6):1945-1951. PubMed ID: 29016325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential Immune Profiles in Two Pandemic Influenza A(H1N1)pdm09 Virus Waves at Pandemic Epicenter.
    Arriaga-Pizano L; Ferat-Osorio E; Rodríguez-Abrego G; Mancilla-Herrera I; Domínguez-Cerezo E; Valero-Pacheco N; Pérez-Toledo M; Lozano-Patiño F; Laredo-Sánchez F; Malagón-Rangel J; Nellen-Hummel H; González-Bonilla C; Arteaga-Troncoso G; Cérbulo-Vázquez A; Pastelin-Palacios R; Klenerman P; Isibasi A; López-Macías C
    Arch Med Res; 2015 Nov; 46(8):651-8. PubMed ID: 26696552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serological report of pandemic and seasonal human influenza virus infection in dogs in southern China.
    Yin X; Zhao FR; Zhou DH; Wei P; Chang HY
    Arch Virol; 2014 Nov; 159(11):2877-82. PubMed ID: 24965232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada.
    Skowronski DM; Chambers C; Sabaiduc S; De Serres G; Winter AL; Dickinson JA; Gubbay JB; Drews SJ; Martineau C; Charest H; Krajden M; Bastien N; Li Y
    J Infect Dis; 2017 Dec; 216(12):1487-1500. PubMed ID: 29029166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing Antigenic Drift of Seasonal Influenza A(H3N2) and A(H1N1)pdm09 Viruses.
    Tewawong N; Prachayangprecha S; Vichiwattana P; Korkong S; Klinfueng S; Vongpunsawad S; Thongmee T; Theamboonlers A; Poovorawan Y
    PLoS One; 2015; 10(10):e0139958. PubMed ID: 26440103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The priming effect of previous natural pandemic H1N1 infection on the immunogenicity to subsequent 2010-2011 influenza vaccination in children: a prospective cohort study.
    Kang EK; Eun BW; Kim NH; Lim JS; Lee JA; Kim DH
    BMC Infect Dis; 2016 Aug; 16(1):438. PubMed ID: 27549626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology of 2009 pandemic influenza A virus subtype H1N1 among Kenyans aged 2 months to 18 years, 2009-2010.
    Wong KK; Bulimo WD; Magana J; Achilla RA; Schwarcz SK; Simwa M; Majanja JM; Wadegu MO; Osuna FA; Mukunzi SO; Mwangi JK; Wangui JM; Muthoni JN; Njiri JO; Obura BD; Opot BH; Mitei KK; Barani J; Lifumo S; Schnabel DC
    J Infect Dis; 2012 Dec; 206 Suppl 1():S68-73. PubMed ID: 23169975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Host immune response to A(H1N1)pdm09 vaccination and infection: a one-year prospective study on six cohorts of subjects.
    Liu W; Ma MJ; Tang F; He C; Zhang XA; Jiang LF; Xin DS; Hu CY; Looman C; Cao WC
    Vaccine; 2012 Jul; 30(32):4785-9. PubMed ID: 22633868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of monovalent 2009 pandemic influenza A virus subtype H1N1 and 2010-2011 trivalent inactivated influenza vaccines in Wisconsin during the 2010-2011 influenza season.
    Bateman AC; Kieke BA; Irving SA; Meece JK; Shay DK; Belongia EA
    J Infect Dis; 2013 Apr; 207(8):1262-9. PubMed ID: 23341536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy.
    Ottóffy G; Horváth P; Muth L; Sólyom A; Garami M; Kovács G; Nyári T; Molnár D; Pauler G; Jankovics I
    Pediatr Blood Cancer; 2014 Jun; 61(6):1013-6. PubMed ID: 24395342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.